- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03141944
Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease (IMPACT)
Improvement of Hypodopaminergic Syndrome With Dopaminergic Treatment in Early Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
All patients to be included have been clinically described in the early phase of their disease, before instauration of dopaminergic treatment, in the context of a former study ("Non Motor Aspects in De Novo Parkinson's Disease (Honeymoon) NCT02786667") between june 2012 and june 2016.
3 to 5 years after this study, those patients who started dopaminergic treatment will be evaluated again.
The objective of this study, which takes place 3 to 5 year after the initial evaluation, is to measure the evolution of apathy and other symptoms of the hypodopaminergic syndrome.
Secondary objectives are the evolution of other parameters including pain, personality and behavior. All parameters measured have been determined of each patient in the Honeymoon study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Grenoble, France, 38043
- University hospital of Grenoble
-
Lyon, France
- Hôpital Neurologique Pierre Wertheimer
-
Poitiers, France
- Centre Expert Régional pour la maladie de Parkinson
-
Strasbourg, France
- Hôpital de HAUTEPIERRE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients who participated in "Non Motors Aspects in De Novo Parkinson's Disease (Honeymoon)" NCT02786667
- Patients under dopaminergic treatment, with stable dopaminergic treatment for at least 2 months
- Patients with medical insurance
- signed informed consent
Exclusion Criteria:
- diagnosis other than Parkinson's Disease
- dementia (Mattis <130)
- patients protected by law (i.e. pregnant or parturient women)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Apathetic patients
De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion. All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the "Starkstein scale of apathy" |
The degree of apathy will be evaluated with the "Starkstein scale of Apathy"
|
Non-apathetic patients
De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion. All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the "Starkstein scale of apathy" |
The degree of apathy will be evaluated with the "Starkstein scale of Apathy"
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of apathy in Parkinson's disease
Time Frame: 1day
|
Evolution of apathy in Patients with Parkinson's disease under dopaminergic treatment.
The degree of apathy is evaluated with the "Starkstein Scale of Apathy".
|
1day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evolution of hypodopaminergia in Parkinson's disease
Time Frame: 1 day
|
Evolution of hypodopaminergic symptoms in Patients with Parkinson's disease under dopaminergic treatment.
Hypodopaminergic symptoms are evaluated with different scales: ECMP (behavioral evaluation in Parkinsons's disease) for depression and anxiety, STAI (State-trait-anxiety inventory, self-assessment-questionnaire for anxiety, BDI (Beck depression inventory) for depression, PFS-16 (Piper Fatigue Sale) for fatigue.
Hypodopaminergia is the expressed as the sum of its symptoms.
|
1 day
|
Apparition of hyperdopaminergic symptoms in Parkinson's disease
Time Frame: 1 day
|
Apparition of hyperdopaminergic symptoms in patients with Parkinson's disease under dopaminergic treatment, with the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the ECMP scale.
|
1 day
|
Evolution of impulsivity in Parkinson's disease
Time Frame: 1 day
|
Evolution of impulsivity in patients with Parkinson's disease under dopaminergic treatment.
Evaluation with a self-assessment-questionnaire (UPPS Impulsive Behavior Scale)
|
1 day
|
Evolution of personality in Parkinson's disease
Time Frame: 1 day
|
Evolution of personality in patients with Parkinson's disease under dopaminergic treatment with the self-assesment-questionnaire "Temperament and Character Inventory" (TCI).
|
1 day
|
Evolution of pain in Parkinson's disease
Time Frame: 1 day
|
Evolution of pain in patients with Parkinson's disease under dopaminergic treatment with the self-assessment-questionnaire NPSI (Neuropathic Pain Symptom Inventory).
|
1 day
|
Evolution of quality of life in Parkinson's disease
Time Frame: 1 day
|
Evolution of quality of life in patients with Parkinson's disease under dopaminergic treatment with the self-assessment-questionnaire PDQ39 (Parkinson's disease questionnaire).
|
1 day
|
Evolution of somnolence in Parkinson's disease
Time Frame: 1 day
|
Evolution of somnolence in patients with Parkinson's disease under dopaminergic treatment with the ECMP scale.
|
1 day
|
Evolution of eating behavior in Parkinson's disease
Time Frame: 1 day
|
Evolution of eating behavior in patients with Parkinson's disease under dopaminergic treatment with the self-assesment-questionnaire "Dutch Eating Behavior Questionnaire" - DEBQ.
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna Castrioto, MD, University Hospital, Grenoble
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 38RC16.184
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Starkstein scale of Apathy
-
Rennes University HospitalCompleted
-
Institut National de la Santé Et de la Recherche...CompletedFrontotemporal Dementia | Behavior | Apathy
-
University of ZurichUnknownPsychological Distress | Relatives | PolytraumaSwitzerland
-
Bogomolets National Medical UniversityCompletedChronic Pain | Psychological DisordersUkraine
-
Memorial Sloan Kettering Cancer CenterRecruitingEndometrial CancerUnited States
-
Assiut UniversityNot yet recruitingObsessive-Compulsive Disorder
-
Nantes University HospitalTerminated
-
CelgeneCompletedMyelodysplastic Syndromes | Multiple Myeloma | Leukemia Myeloid Acute | Leuklemia, Lymphocytic, ChronicSpain
-
Uskudar State HospitalNot yet recruitingPulmonary Disease | Pulmonary Rehabilitation | Telehealth
-
Instituto Mexicano del Seguro SocialCompletedCovid19 | Post Partum Depression | Breast Feeding, ExclusiveMexico